OGN · Organon
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $14.58
Note written ·
Price against the kill line
4.7% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $14.58, on record since 10 November 2026. The shares are up 1.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $14.58, 5% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 30 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 1,574
- Revenue, change on a year (%)
- −1.7
- Gross margin (%)
- 55.2
- Free cash flow, four quarters ($M)
- 675
- Net cash, cash less debt ($M)
- −7,099
- Price to earnings (×)
- 17.1
- Enterprise value to sales (×)
- 1.8
- Free-cash-flow yield (%)
- 18.5
All filed numbers
What Organon reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) |
|---|---|---|---|
| first filed | 1,574 | −1.7 | 55.2 |
| first filed | 1,558 | −2.3 | 54.4 |
| first filed | 1,460 | −3.5 | 53.6 |
| first filed | 1,507 | −5.3 | 49.2 |
| first filed | 1,602 | +1.3 | 53.5 |
| first filed | 1,594 | −0.8 | 54.8 |
| Pre-tax income ($M) | 255 |
| Net income ($M) four quarters: 213 | 164 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +4.5 |
| Operating cash flow ($M) | 843 |
| Capital spending ($M) | 168 |
| Free cash flow ($M) | 675 |
| Cash and short-term investments ($M) | 1,455 |
| Debt ($M) non-current long-term debt plus current debt | 8,554 |
| Net cash, cash less debt ($M) | −7,099 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 1,480 |
| Inventory ($M) | 1,355 |
| Shareholders' equity ($M) | 1,193 |
| Market value ($M) | 3,650 |
| Enterprise value, market value plus net debt ($M) | 10,749 |
| Enterprise value to sales (×) | 1.8 |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | 17.1 |
| Price to book value (×) | 3.1 |
| Free-cash-flow yield (%) | 18.5 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 7.2% of shares outstanding sold short, 8.6 days of average trading to cover, −0.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $353K | $200K |
The thesis
Organon & Co. trades as a completion case on Sun Pharma's $14.00-per-share cash acquisition, and the remaining regulatory clearances decide it. The adjusted close was $13.85 on 9 November 2026, equal to the 52-week high and below the $14.00 cash price, so a completed deal pays a small amount more and a failed deal costs a great deal more.
The merger agreement is dated 26 April 2026, and stockholders approved it at the 23 July 2026 special meeting, per Organon's Form 8-K. Organon reported third-quarter results on 30 October 2026 through its Form 10-Q, with no earnings call. A Quartr summary of that filing puts revenue near $1.57 billion, down 2% year over year, and says the deal is still expected to close in early 2027. A German financial site, Kapitalmarktexperten, reported on 2 November 2026 that Sun Pharma expects the close in the fourth quarter of its fiscal 2027 (January to March 2027), and that the European Commission has set a provisional decision deadline of 3 December 2026.
The story is well known: the terms have been public since 27 April 2026, the vote is done, and the shares now sit at their high. Since the 27 October 2026 close of $13.75, the shares gained a dime while the remaining approvals are still pending.
Bullish and bearish views on Organon & Co.
The bull case on Organon & Co. (OGN), in brief: stockholder approval is done. The bear case: the payoff is capped at $14.00.
Bull case
- Stockholder approval is done. Organon's 23 July 2026 Form 8-K records approval of the merger agreement. The remaining conditions are regulatory or customary.
- Most approvals reportedly obtained. Kapitalmarktexperten reported on 2 November 2026, citing media reports, that Sun Pharma says most regulatory approvals are in hand and some are outstanding. The article is a secondary source and does not list which clearances remain.
- The price is fixed in cash. The agreement sets $14.00 per share with no stock component. Benzinga reported on 27 April 2026 that the price is a 103% premium to the pre-announcement price.
- A dated European step exists. The Commission's provisional deadline of 3 December 2026 gives the first scheduled public marker on regulatory progress.
- Analysts sit at the deal price. Piper Sandler on 28 April 2026 and BNP Paribas on 29 April 2026 each moved to Neutral with a $14 target, per Benzinga.
Bear case
- The payoff is capped at $14.00. The consideration is fixed in cash. With the close at $13.85 on 9 November 2026, a delay or a regulatory remedy outweighs the remaining gain.
- The standalone business is shrinking. The Quartr summary of the Q3 2026 Form 10-Q shows revenue down 2% year over year. Organon's Q2 2026 Form 10-Q reported revenue of $1,558 million, also down 2%. On 30 April 2026 Benzinga reported Q1 adjusted earnings of $0.71 per share against a $0.83 estimate.
- A failed deal reprices sharply. Before the announcement, the shares traded between $6.36 and $6.90 in early April 2026. A termination would point the price back toward that area.
- The deadline can move. The outside date is 26 January 2027. Section 9.2 of the agreement allows a conditional extension to 26 April 2027 if regulatory conditions are still open.
- A provisional deadline is not a clearance. Kapitalmarktexperten noted that the 3 December 2026 date does not itself approve the deal.
Price setup
The adjusted close was $13.85 on 9 November 2026, which is also the 52-week high. The three-month price change was 1.7%. The 14-day relative strength index (RSI), a momentum gauge on a 0–100 scale, was 67.7, up from 41.7 on 27 October 2026.
Crowding evidence is thin. The company holds no earnings calls, and its recent releases are medical-meeting data on the biosimilar HADLIMA (8 November 2026) and the skin cream VTAMA (5 November 2026). Organon declared a quarterly dividend of $0.02 per share on 30 October 2026, per Kapitalmarktexperten, with a 9 November 2026 record date and a 10 December 2026 payment date. No insider selling or share issuance appeared in company news.
It sits well under the last close and the 52-week high.
Catalysts ahead
- 3 December 2026: European Commission provisional decision deadline on the Sun Pharma acquisition. A clearance would remove one remaining regulatory condition; a deeper review would push completion toward the outside date.
- 10 December 2026: Payment date for Organon's $0.02 quarterly dividend. Shows Organon continuing normal capital returns while the deal is pending.
- 26 January 2027: Initial merger outside date. A termination-right milestone; an extension to 26 April 2027 would show regulatory approvals are still open.
What would change the view
A daily close above $14.58, 5% above the last close (11 November 2026), would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
The shares trade on deal news and the cash price, not on pharma or health-care indexes. Consideration is all cash, so the price carries no exposure to Sun Pharma's equity or the rupee. Broad market moves matter mainly through merger-arbitrage spreads and the probability the market assigns to completion.
The evidence, claim by claim (8)
- Adjusted daily close was $13.85 on 9 November 2026, equal to the 52-week high; three-month price change 1.7%; 14-day RSI 67.7. Split/dividend-adjusted daily price series · as of
- Organon reported Q3 2026 results through its Form 10-Q on 30 October 2026; a Quartr summary puts revenue near $1.57 billion, down 2% year over year, with the Sun Pharma deal expected to close in early 2027. Quartr Q3 2026 earnings summary; Organon Form 10-Q · as of
- European Commission set a provisional decision deadline of 3 December 2026; Sun Pharma reportedly says most approvals are obtained and expects closing in the fourth quarter of its fiscal 2027. Kapitalmarktexperten, 2 November 2026 · as of
- Organon declared a $0.02 quarterly dividend, record date 9 November 2026, payable 10 December 2026. Kapitalmarktexperten, 2 November 2026 · as of
- Stockholders approved the Sun Pharma merger agreement at the special meeting. Organon Form 8-K, special meeting results · as of
- Q2 2026 revenue was $1,558 million, down 2% year over year. Organon Q2 2026 Form 10-Q · as of
- Merger agreement sets a 26 January 2027 outside date with a conditional extension to 26 April 2027. Agreement and Plan of Merger dated 26 April 2026, section 9.2 · as of
- Piper Sandler and BNP Paribas each moved to Neutral with a $14 price target. Benzinga, 28 April 2026 and 29 April 2026 · as of
Sources
- Organon (OGN) Q3 2026 earnings summary · quartr.com
- Organon Aktie: Die Dividende fließt weiter · kapitalmarktexperten.de ·
- Sun Pharma Acquisition Anchors Organon Outlook Amidst Nexplanon Regulatory Scrutiny · panabee.com ·
- Finviz
Related · shared themes
GPN
Global Payments
Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
BMBL
Bumble
Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing…
BRZE
Braze
Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P…